Last updated: September 7, 2026
Alirocumab, marketed as Praluent, is a fully human monoclonal antibody targeting PCSK9. Sanofi and Regeneron commercialize the drug under a restructured collaboration, with Regeneron responsible for U.S. commercialization and Sanofi retaining major international responsibilities. The product remains commercially viable because of its cardiovascular-risk reduction indication, established payer coverage, and use in patients who cannot reach low-density lipoprotein cholesterol targets with statins. Its growth is constrained by high competition from evolocumab, inclisiran, oral lipid-lowering therapies, and aggressive price management.
Public financial disclosures indicate that Praluent has developed into a mid-sized product rather than a blockbuster. Global sales have generally remained in the low-to-mid hundreds of millions of euros annually, while Repatha has established a materially larger revenue base. The primary long-term risks are biologic competition, contracting pressure, patent expiry near the end of the decade, and reduced demand for injectable therapies as oral and longer-acting alternatives expand.
What is alirocumab and how does Praluent work?
Alirocumab is a fully human IgG1 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9, or PCSK9. PCSK9 binding to low-density lipoprotein receptors on hepatocytes promotes receptor degradation. Alirocumab inhibits that interaction, increasing hepatic LDL-receptor recycling and accelerating clearance of LDL cholesterol from the bloodstream.
The FDA approved Praluent in July 2015 as an adjunct to diet and maximally tolerated statin therapy for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, or HeFH, and patients with atherosclerotic cardiovascular disease requiring additional LDL reduction.[1]
The standard adult doses are:
| Dose |
Administration |
Typical use |
| 75 mg |
Subcutaneous injection every two weeks |
Initial treatment for many patients |
| 150 mg |
Subcutaneous injection every two weeks |
Patients requiring greater LDL reduction |
| 300 mg |
Subcutaneous injection every four weeks |
Monthly administration option |
The product is supplied in single-dose prefilled pens and syringes. The 300 mg monthly regimen provides a convenience advantage for some patients, although monthly dosing can produce greater LDL variability than biweekly administration in certain patients.
What FDA approvals and label expansions support alirocumab sales?
Praluent’s original approval focused on LDL reduction. The FDA later expanded the label to include reduction of the risk of major adverse cardiovascular events in adults with established cardiovascular disease.[2]
Key regulatory milestones include:
| Date |
Regulatory event |
| July 2015 |
Initial FDA approval for primary hyperlipidemia and HeFH |
| 2015-2016 |
European and other international approvals for hypercholesterolemia |
| 2017 |
FDA approval for reducing cardiovascular events in adults with established cardiovascular disease |
| 2019 |
ODYSSEY OUTCOMES data supported cardiovascular outcome positioning |
| 2023 |
FDA approval expanded use to pediatric patients aged 8 years and older with HeFH |
The cardiovascular-outcomes indication improved the product’s clinical positioning. The ODYSSEY OUTCOMES trial showed that alirocumab reduced ischemic cardiovascular events in patients who had experienced acute coronary syndrome and were receiving intensive or maximally tolerated statin therapy.[3]
The pediatric HeFH expansion provides a small but defensible market extension. It is unlikely to materially change the product’s overall revenue profile because pediatric dyslipidemia is a limited population and payer authorization remains restrictive.
How has alirocumab revenue changed over time?
Praluent has generated substantially less revenue than the original commercial expectations for the PCSK9 class. High launch pricing, prior-authorization restrictions, physician hesitation, and competition from Repatha affected uptake during the first several years.
Sanofi financial reporting indicates that Praluent sales have remained broadly stable rather than following the rapid growth curve initially projected for the class. The following trajectory uses rounded figures from Sanofi annual reporting and company disclosures:
| Year |
Approximate Sanofi-reported Praluent sales |
Commercial interpretation |
| 2018 |
About €250 million |
Early access restrictions and class pricing pressure |
| 2019 |
About €300 million |
Improved reimbursement and cardiovascular-outcomes positioning |
| 2020 |
About €300 million |
Stable demand during pandemic disruption |
| 2021 |
About €300 million |
Mature product with continued international use |
| 2022 |
About €300 million |
Stable sales despite competing PCSK9 products |
| 2023 |
About €300 million |
Limited growth, with pricing and channel effects offsetting volume gains |
Exact presentation varies by annual report, geographic accounting, currency conversion, and collaboration treatment. Sanofi’s reported figure does not represent the full economic value retained by every party in the Regeneron relationship. Regeneron reports collaboration-related economics separately and does not present Praluent as a standalone product-sales line equivalent to Sanofi’s reporting.
The revenue profile is therefore best characterized as mature and durable, with limited probability of returning to high-growth status without a major label expansion or a material change in payer coverage.
How does alirocumab compare with evolocumab and inclisiran?
Alirocumab competes most directly with Amgen’s evolocumab, marketed as Repatha. Inclisiran, marketed as Leqvio by Novartis, competes through a different biological mechanism and dosing schedule.
| Attribute |
Alirocumab |
Evolocumab |
Inclisiran |
| Brand |
Praluent |
Repatha |
Leqvio |
| Company |
Sanofi/Regeneron |
Amgen |
Novartis |
| Mechanism |
PCSK9 monoclonal antibody |
PCSK9 monoclonal antibody |
PCSK9-directed small interfering RNA |
| Administration |
Every two weeks or monthly |
Every two weeks or monthly |
Initial dose, three months later, then every six months |
| Cardiovascular outcomes |
Positive ODYSSEY OUTCOMES trial |
Positive FOURIER trial |
Outcomes data historically less mature |
| Main strength |
Established outcomes evidence and flexible dosing |
Larger commercial scale and strong formulary presence |
Very low administration frequency |
| Main weakness |
Competitive contracting and mature patent estate |
Similar injection and access constraints |
Buy-and-bill logistics and outcomes-adoption questions |
Repatha has generally achieved greater commercial scale. The products have similar clinical roles, so formulary placement, net price, injection-device performance, physician familiarity, and patient adherence can determine product selection more than pharmacology.
Inclisiran creates a different competitive threat. Its twice-yearly maintenance schedule may appeal to patients with poor adherence or limited ability to self-administer injections. Its commercial model, which can involve administration in a healthcare setting, also differs from the pharmacy-benefit model used for many self-injected PCSK9 antibodies.
Oral competitors include ezetimibe, bempedoic acid, and fixed-dose combinations. These products generally have lower acquisition costs and simpler administration. They can delay or eliminate the need for injectable PCSK9 treatment in patients with moderate additional LDL-lowering requirements.
What patents protect alirocumab and when does Praluent lose exclusivity?
Alirocumab is protected primarily by biologic composition-of-matter and antibody-related patent claims rather than by a conventional small-molecule patent portfolio. The core U.S. estate includes patents directed to antibodies that bind PCSK9 and related pharmaceutical compositions.
Publicly identified U.S. patents associated with Praluent include:
| Patent |
General subject matter |
Reported term profile |
| U.S. Patent No. 8,829,165 |
Anti-PCSK9 antibodies |
Expiration generally reported around 2029, subject to patent-term adjustment |
| U.S. Patent No. 9,340,614 |
Anti-PCSK9 antibody compositions and related claims |
Expiration generally reported around 2029 |
| Additional continuation patents |
Antibody sequences, formulations, and use claims |
Individual expiration dates vary |
The relevant U.S. regulatory exclusivity is biologic exclusivity under the Public Health Service Act, not small-molecule New Chemical Entity exclusivity. Praluent’s core biologic exclusivity period has expired. The commercial barrier now depends primarily on patents, the complexity of manufacturing, FDA biosimilar requirements, and the economics of entering a relatively mature market.
The most commercially important U.S. patent barriers are generally expected to run into 2029. The precise effective dates can vary based on patent-term adjustment, terminal disclaimers, maintenance status, claim scope, and jurisdiction. European and other national rights also differ because supplementary protection certificates, national validations, and local litigation can change the practical entry date.
What is the Orange Book status of Praluent?
Praluent is not an ordinary Orange Book small-molecule product. It was approved as a biologic under a biologics license application, or BLA, and biosimilar applicants use the 351(k) pathway rather than the abbreviated new drug application pathway.
The relevant FDA reference resources are:
- The Purple Book for biologic reference products and biosimilars.
- BLA patent-dispute procedures under the Biologics Price Competition and Innovation Act.
- FDA labeling and approval records for the reference product.
- Patent databases and court dockets for claim-level analysis.
A conventional Paragraph IV generic challenge is therefore not the expected pathway for alirocumab. A biosimilar applicant may instead assert that listed patents are invalid, unenforceable, or not infringed, depending on the statutory and litigation strategy used.
Which companies are challenging alirocumab exclusivity?
No biosimilar competitor has established the same market presence against Praluent as generic manufacturers have against traditional small molecules. The likely competitive entrants are large biologics manufacturers with experience in antibody development, cell-line production, analytical characterization, and payer contracting.
Potential entry barriers include:
- Demonstrating biosimilarity to a structurally complex antibody.
- Reproducing the reference product’s critical quality attributes.
- Establishing an economically viable manufacturing process.
- Funding patent litigation before commercial launch.
- Obtaining formulary access against entrenched PCSK9 products.
- Supporting physician adoption without a differentiated device or price.
Because Praluent has annual sales in the hundreds of millions rather than several billion dollars, the market may not justify multiple biosimilar entrants. A first biosimilar could gain leverage through discounting, but the net-price opportunity would be narrower than in larger antibody markets.
What patent litigation affects alirocumab?
The most important historical litigation involved Amgen’s patents covering PCSK9 antibodies. Amgen sued Sanofi and Regeneron over patents associated with the PCSK9 antibody class after Praluent launched. The dispute produced a district-court injunction against Praluent, which the Federal Circuit later stayed while the litigation continued.
The parties reached a settlement in 2019. Under the settlement, Praluent remained on the market, and the companies agreed to terms covering continued commercialization and patent disputes.[4] The settlement removed the immediate risk of a U.S. injunction and allowed Sanofi and Regeneron to continue selling Praluent through the remaining patent period.
The litigation matters commercially because it confirmed that PCSK9 antibody patents could create launch-blocking risk even after FDA approval. It also reduced the probability of near-term disruption to Praluent supply and allowed the parties to focus on market access rather than an injunction fight.
How strong is the alirocumab patent estate?
The estate is commercially meaningful but not impenetrable.
Strengths
- Core antibody claims can create substantial barriers if they cover the biosimilar’s binding characteristics or sequence.
- Patent protection extends well beyond the initial biologic exclusivity period.
- The product has clinical-outcomes data that support a broad commercial indication.
- Formulation, device, and manufacturing claims can complicate biosimilar development.
Weaknesses
- PCSK9 antibodies have been subject to extensive validity litigation.
- Broad genus claims can face written-description and enablement challenges.
- The market already has a clinically similar competitor.
- A biosimilar entrant could use price competition rather than clinical differentiation.
- The product’s moderate revenue limits the value of prolonged patent litigation.
Patent strength is therefore best assessed as moderate to strong through the late 2020s, with meaningful but not unlimited protection against biosimilar entry.
What formulation and manufacturing protections apply to Praluent?
Praluent’s protection extends beyond the antibody sequence. Relevant technical areas include:
- Stabilized liquid antibody formulations.
- Buffer and excipient systems.
- Subcutaneous delivery configurations.
- Prefilled pen and syringe presentations.
- Manufacturing processes for antibody expression and purification.
- Control of aggregation, particle formation, and immunogenicity.
- Container-closure and storage conditions.
Formulation patents can delay a biosimilar only when their claims are valid and difficult to design around. They are generally weaker than core composition claims because a biosimilar manufacturer may develop a different excipient system or device while maintaining the same active antibody.
Manufacturing remains a practical barrier even when patent claims can be designed around. A biosimilar sponsor must establish comparability, process consistency, impurity control, potency, and stability at commercial scale.
What licensing deals govern alirocumab commercialization?
Sanofi and Regeneron began their antibody collaboration in 2007. The arrangement included joint development and commercialization economics for PCSK9 antibodies and other products. The companies later restructured the collaboration, with Regeneron assuming greater responsibility for U.S. Praluent commercialization while Sanofi retained international commercial responsibilities in major markets.
The restructuring reduced some operational overlap but did not eliminate the economic relationship between the companies. Revenue attribution can therefore differ between Sanofi’s product-sales reporting and Regeneron’s collaboration-revenue reporting.[5]
No major third-party licensing deal has transformed Praluent’s commercial outlook. The product’s economics remain primarily tied to the Sanofi-Regeneron relationship, payer contracts, and the rights retained in individual territories.
What generic and biosimilar launch scenarios exist for alirocumab?
The most likely U.S. launch scenarios are:
| Scenario |
Timing |
Commercial effect |
| No biosimilar before core patent expiry |
Through approximately 2029 |
Continued mature-brand revenue and selective payer coverage |
| First biosimilar launch after patent settlement |
Around or after core patent expiry |
Rapid net-price erosion, with retention of some brand share |
| Multiple biosimilars |
After broad patent clearance |
Severe discounting and reduced brand utilization |
| Formulation or device differentiation |
Any time after regulatory entry |
Potential premium for convenience or administration support |
A single biosimilar may not produce immediate substitution because biologics are not automatically interchangeable in the same manner as small-molecule generics. Payer policies, pharmacy versus medical-benefit coverage, prescriber preference, and state substitution rules will influence uptake.
What is the revenue exposure to Praluent for Sanofi and Regeneron?
Praluent is strategically relevant but not a central revenue driver for either company.
For Sanofi, the product is small relative to Dupixent, vaccines, immunology products, diabetes medicines, and other major franchises. A 50% decline in Praluent sales would have limited effect on consolidated revenue but could reduce the value of the cardiovascular franchise and international commercial infrastructure supporting the drug.
For Regeneron, Praluent is also small relative to Eylea and other major products. The product contributes collaboration economics and validates the company’s antibody-discovery platform, but it is unlikely to materially determine overall valuation.
The principal financial exposure is therefore concentrated at the product level. The companies face revenue erosion, contracting pressure, and reduced portfolio productivity rather than a major enterprise-level patent cliff.
Key Takeaways
- Alirocumab is a mature PCSK9 inhibitor with durable but moderate annual sales.
- Praluent’s main competitors are Repatha, Leqvio, ezetimibe, bempedoic acid, and low-cost statin-based regimens.
- Cardiovascular-outcomes evidence and the expanded pediatric indication support continued utilization.
- The product is a biologic and is not challenged through a conventional Paragraph IV generic pathway.
- Core U.S. patent protection is generally expected to extend into approximately 2029, subject to patent-specific adjustments and litigation outcomes.
- The 2019 Amgen settlement removed the immediate risk of a U.S. injunction.
- Biosimilar entry is technically and commercially feasible but may be delayed by patent costs and the product’s moderate revenue opportunity.
- Praluent is strategically important to the Sanofi-Regeneron collaboration but is not a major consolidated-revenue driver for either company.
FAQs About Alirocumab Market and Patent Risk
Is alirocumab a biosimilar or a reference biologic?
Alirocumab is the reference biologic marketed as Praluent. Any later competitor would generally seek approval as a biosimilar under the FDA’s 351(k) pathway.
Does alirocumab have cardiovascular-outcomes data?
Yes. The ODYSSEY OUTCOMES trial found that alirocumab reduced major adverse cardiovascular events in high-risk patients after acute coronary syndrome who were receiving intensive or maximally tolerated statin therapy.
When could a Praluent biosimilar launch in the United States?
The commercially relevant patent barrier is generally expected to extend into approximately 2029, although a launch could occur earlier through patent invalidation, noninfringement, licensing, or settlement.
Which PCSK9 drug has the larger commercial position?
Evolocumab, marketed as Repatha, has generally achieved the larger commercial position. Alirocumab remains competitive through its outcomes evidence, international reach, dosing flexibility, and established payer coverage.
Is Praluent exposed to an Orange Book Paragraph IV challenge?
Not in the conventional small-molecule sense. Praluent is a BLA-approved biologic, so the relevant framework involves the Purple Book and biologic patent procedures rather than a standard abbreviated new drug application and Paragraph IV filing.
References
- U.S. Food and Drug Administration. (2015). FDA approves Praluent to treat certain patients with high cholesterol.
- U.S. Food and Drug Administration. (2017). Praluent prescribing information.
- Schwartz, G. G., Steg, P. G., Szarek, M., et al. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine, 379(22), 2097-2107.
- Regeneron Pharmaceuticals, Inc. (2019). Regeneron and Sanofi announce settlement of patent litigation with Amgen regarding Praluent.
- Sanofi. (2024). Universal registration document and annual financial report 2023.
